---
title: "Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289098947.md"
description: "On June 8, 2026, at 22:01 CET in Mechelen, Belgium, Lakefront Bio therapeutics NV shared news of Dr. Eric Hedrick's appointment as Chief Medical Officer. This move aligns with the company's strategic shift after acquiring Ouro Medicines operational assets on June 4, 2026. Dr. Hedrick, MD, will now report to CEO Henry Gosebruch and become a member of the Management Committee. Lakefront Bio therapeutics NV, listed on Euronext & NASDAQ as LKFT, continues to focus on growth and transformation in its leadership structure."
datetime: "2026-06-08T20:03:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289098947.md)
  - [en](https://longbridge.com/en/news/289098947.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289098947.md)
---

# Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer

On June 8, 2026, at 22:01 CET in Mechelen, Belgium, Lakefront Bio therapeutics NV shared news of Dr. Eric Hedrick's appointment as Chief Medical Officer. This move aligns with the company's strategic shift after acquiring Ouro Medicines operational assets on June 4, 2026. Dr. Hedrick, MD, will now report to CEO Henry Gosebruch and become a member of the Management Committee. Lakefront Bio therapeutics NV, listed on Euronext & NASDAQ as LKFT, continues to focus on growth and transformation in its leadership structure.

### Related Stocks

- [LKFT.US](https://longbridge.com/en/quote/LKFT.US.md)

## Related News & Research

- [Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Posts Earnings Results, Beats Expectations By $1.01 EPS](https://longbridge.com/en/news/295456212.md)
- [Lakefront Biotherapeutics Buys Back 97,497 Shares Under Ongoing Repurchase Program](https://longbridge.com/en/news/294869610.md)
- [Lakefront Biotherapeutics Buys Back Over 104,000 Shares Under June 2026 Repurchase Program](https://longbridge.com/en/news/291976749.md)
- [Lakefront Biotherapeutics repurchases own stock for EUR 1.92 million](https://longbridge.com/en/news/290603177.md)
- [LKFT: Returned to profitability in H1 2026 with €16.6M net profit and robust €2.24B cash position](https://longbridge.com/en/news/295487540.md)